Levetiracetam does not alter body weight: Analysis of randomized, controlled clinical trials

Epilepsy Research

Volumn 56, Issue 2-3, 2003, Pages 121-126

  Gidal, Barry E ^a   Sheth, Raj D ^a   Magnus, Leslie ^b   Herbeuval, Anne Francoise ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drug; Epilepsy; Levetiracetam; Weight change

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; EPILEPSY; EVALUATION; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANK SUM TEST; WEIGHT GAIN;

EID: 0345690127     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2003.08.009     Document Type: Article

References (34)

1. Aronne L.J. Epidemiology, morbidity and treatment of overweight and obesity. J. Clin. Psychiatry. 62(Suppl. 23):2001;13-22.
2. Baulac M., Cavalcanti D., Semah F., Arzimanoglou A., Portal J. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open observational study. Seizure. 7:1998;55-82.
3. Bergen D.C., Ristanovic R.K., Waicosky K., Kanner A., Hoeppner T.J. Weight loss in patients taking felbamate. Clin. Neuropharmacol. 18:1995;23-27.
4. Biton V., Mirza W., Montouris G., Vuong A., Hammer A., Barrette P. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 56:2001;172-177.
5. Biton V., Levisohn P., Hoyler S. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J. Child Neurol. 18:2003;133-139.
6. Bourgeois, B.F.D., 1997. Felbamate. Semin. Pediatr. Neurol. 4, 3-8.
7. Bray G., Klein S., Levy B. Topiramate produces dose-related weight loss in obese patients. Diabetes. 51(Suppl. 2):2002;A420-A421. (abstract).
8. Brown R.O., Orr C.D., Hanna D.L., Williams J., Dickerson R.N. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy. 22:2002;831-835.
9. Cilio M.R., Kartashov A.I., Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 47:2001;1-7.
10. Corman C.L., Leung N.M., Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can. J. Neurol. Sci. 24:1997;240-244.
11. DeToledo J.C., Toledo C., DeCerce J., Ramsay R.E. Changes in body weight with chronic high-dose gabapentin therapy. Ther. Drug Monit. 19:1997;394-396.
12. Devinsky O., Vuong A., Hammer A., Barrett P.S. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology. 54:2000;973-975.
13. Dinesen H., Gram L., Andersen T., Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 69:1984;65-69.
14. Faught, E., Ayala, R., Montouris, G.G., Leppik, I.E., Zonisamide 1922 Trial Group, 2001. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57, 1774-1779.
15. Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288:2002;1723-1727.
16. Gadde K.M., Francisy D.M., Wagner H.R., Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 289:2003;1820-1825.
17. Genton P., Bauer J., Duncan S., Taylor A., Balen A.et al. On the association between valproate and polycystic ovary syndrome. Epilepsia. 42:2001;295-304.
18. Gidal B.E., Anderson G.D., Spencer N.W., Maly M.M. Valproate associated weight gain in patients with epilepsy: potential relationship to energy expenditure and metabolism. J. Epilepsy. 9:1996;234-241.
19. Isojarvi J.I.T., Laatikainen T.J., Knip M., Pakarinen A.J.et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 39:1996;579-584.
20. Isojarvi J.I.T., Taubll E., Tapanainen J.S., Pakarinen A.J.et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia. 42:2001;305-310.
21. King J.A., Bayler R.L. Weight gain during add-on using gabapentin. Epilepsia. 36(Suppl. 4):1995;72. (abstract).
22. Lampl Y., Eshel Y., Rapaport A., Sarova-Pinhas I. Weight gain increased appetite and excessive food intake induced by carbamazepine. Clin. Neuropharmacol. 14:1991;251-255.
23. McIntyre R.S., Mancini D.A., McCann S. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 4:2002;207-213.
24. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 282:1999;519-1522.
25. Must A., Spandano J., Coakley E.H., Field A.E.et al. The disease burden associated with overweight and obesity. JAMA. 282:1999;1523-1529.
26. National Heart, Lung and Blood Institute, 2001. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: evidence report. Available: http://www.nhlbi.nih.gov/guidelines/obesity/ ob_gdlns.pdf .
27. Novak G.P., Maytal J., Alshansky A., Eviatar L.et al. Risk of excessive weight gain in epileptic children treated with valproate. J. Child Neurol. 14:1999;490-495.
28. Ogden C.L., Flegal K.M., Carroll M.D., Johnson C.L. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 288:2002;1728-1732.
29. Richard D., Ferland J., Lalonde J., Samson P.et al. Influence of topiramate in the regulation of energy balance. Nutrition. 16:2000;961-966.
30. Rosenfeld W.E., Slater J. Characterization of topiramate-associated weight changes in adults with epilepsy. Epilepsia. 43(Suppl. 7):2002;220-221.
31. Shimizu A., Ikoma R., Shimizu T. Effects and side effects of zonisamide during long-term medication. Curr. Ther. Res. 47:1990;696-706.
32. Verotti A., Morresi S., deMartino M., Morgese G., Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology. 53:1999;230-232.
33. Welty T.E., Kuzniecky R.I., Limdi N., Faught E., 2001. Weight loss associated with use of zonisamide in European and US clinical trials. Epilepsia 42, 262 (abstract).
34. York D.A., Singer L., Thomas S., Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 16:2000;967-975.